Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS-K IPG8
- Development stage
- Preclinical
- Lead developer
- JSK Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
JS-K IPG8 is a preclinical-stage small molecule nitric oxide (NO) donor being developed by JSK Therapeutics for the treatment of melanoma. As an arylated diazeniumdiolate prodrug, JS-K is designed to release nitric oxide upon activation by glutathione S-transferases (GST), an enzyme family frequently overexpressed in cancer cells. This targeted release of nitric oxide induces intracellular oxidative stress, DNA damage, and apoptosis specifically in malignant cells while sparing normal tissues. JSK Therapeutics is investigating JS-K IPG8 as a potential therapeutic option for melanoma.
- Other names
- O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolateO2-(2,4-dinitrophenyl)-1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate
02
Targets
GST (Glutathione S-transferase alpha 3)
Beyond the preview
Go deeper on JS-K IPG8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS-K IPG8.